HK Stock Market Move | State-owned bank stocks continue to rise, and listed banks announce dividends intensively. The dividend attribute is expected to continue to be favored by the market.
Domestic banking stocks continue to rise. As of the time of writing, Huishang Bank (03698) rose by 3.12% to 5.29 Hong Kong dollars; China Construction Bank (00939) rose by 2.76% to 8.93 Hong Kong dollars; Industrial and Commercial Bank of China (01398) rose by 2.58% to 7.16 Hong Kong dollars; and Bank of Communications (03328) rose by 2.54% to 7.67 Hong Kong dollars.
Domestic bank stocks continue to rise, as of the time of writing, HUISHANG BANK (03698) is up 3.12% at HKD 5.29, China Construction Bank Corporation (00939) is up 2.76% at HKD 8.93, Industrial and Commercial Bank of China (01398) is up 2.58% at HKD 7.16, and BANKCOMM (03328) is up 2.54% at HKD 7.67.
On the news front, listed banks have recently disclosed announcements on the implementation of equity distribution for 2025. Data shows that the total cash dividends of A-share listed banks for the whole of 2025 amount to approximately 645.6 billion yuan, reaching a new historical high. The total dividend amount of the six major state-owned banks is as high as 427.4 billion yuan, with dividend rates generally maintained at 30% or above.
Galaxy Securities believes that the long-term low interest rate environment continues, the asset shortage logic has not fundamentally changed, and the dividend value of banks is expected to continue to be favored by the market. The institution estimates that the average dividend yield of listed banks is around 4.44% currently, which is still more cost-effective compared to fixed-income assets. With the increased and normalized dividend payout of banks, the bank sector's high dividend and stable dividend distribution characteristics are still prominent, attracting long-term funds such as insurance assets. The dividend value still has room to grow, and continuous attention is needed.
Related Articles

QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.
QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

RECOMMEND





